Drugs / Natrunix
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06590090 | Jul 2026 → Jan 2027 expected | rheumatoid arthritis | XBiotech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05363891 | Aug 2023 → Oct 2024 | rheumatoid arthritis | XBiotech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05363917 | Jun → Dec 2022 | rheumatoid arthritis | XBiotech, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Natrunix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590090 ↗ |
| Action | Inhibit | “exclusively neutralizes interleukin-1α” NCT05363891 ↗ |
| Modality | Monoclonal antibody | “natural human monoclonal antibody” NCT05363891 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT05363891 ↗ |